Total
0
Shares
Microbix Biosystems signs distribution agreement with Labquality Oy
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Dr. Teifel is a leading industry executive with a career spanning over 20 years
  • Dr. Teifel joins AEterna Zentaris having held various positions in the industry
  • In 2004, Dr. Teifel started his first term at AEterna Zentaris where he held positions in the fields of preclinical development and translational research
  • In 2019, Dr. Teifel left AEterna Zentaris to pursue his career in non-clinical research and development at Cleara Biotech in The Netherlands
  • Dr. Teifel holds a degree in biology and his Ph.D. from the Technical University of Darmstadt, Germany
  • AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests
  • AEterna Zentaris Inc. (AEZS) opened trading at C$1.31 per share

AEterna Zentaris (AEZS) has appointed Michael Teifel, Ph.D. as Senior Vice President, Non-Clinical Development and Chief Scientific Officer.

Dr. Teifel is a leading industry executive with a career spanning over 20 years in various therapeutic areas, including endocrinology and oncology.

Over the course of his career, he has gained expertise in the design and implementation of non-clinical development programs for small molecule drugs, peptides, targeted therapies, and biologics, as well as in the continued non-clinical evaluation of drug candidates for global registration.

“We are very pleased to welcome back Dr. Teifel to AEterna Zentaris,” commentedDr. Klaus Paulini, Chief Executive Officer of Aeterna.

“He has vast knowledge and expertise, including having played an integral role for the company previously in the development and registration of macimorelin, which is now the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency. We believe he is a valuable asset to the team as we look to advance our diversified pipeline of pharmaceutical and diagnostic products.”

Dr. Teifel joins AEterna Zentaris having held various positions in the industry with increasing responsibilities in pharmacology, pharmacokinetics, toxicology and translational sciences.

He began his career in the industry at Roche Diagnostics in the area of delivery systems / non-viral gene therapy. In 1999, Dr. Teifel joined the biotech start-up, Munich Biotech in Martinsried, Germany as a co-founder. As head of pharmacology & toxicology, he was responsible for the evaluation and non-clinical development of a novel vascular targeting technology for the development of anti-tumour diagnostics and therapeutics.

In 2004, Dr. Teifel started his first term at AEterna Zentaris where he held several positions in the field of preclinical development and translational research. In his capacity, he was responsible for the preparation of the non-clinical dossier for registration of macimorelin in the U.S. and EU in the indication AGHD.

In 2019, Dr. Teifel left AEterna Zentaris to pursue his career in non-clinical research and development at Cleara Biotech in Utrecht, The Netherlands. As head of translational sciences at Cleara Biotech, he was responsible for translating research on anti-senescent drugs into pre-clinical development in age-related diseases and late-stage cancer.

Dr. Teifel holds a degree in biology and his Ph.D. from the Technical University of Darmstadt, Germany.

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. 

AEterna Zentaris Inc. (AEZS) opened trading at C$1.31 per share.

More From The Market Herald
Assure (TSXV:IOM) approved to list on NASDAQ Capital Market

" Assure (TSXV:IOM) approved to list on NASDAQ Capital Market

Assure Holdings (IOM) has been approved to list its shares on the NASDAQ Capital Market.
Levitee Labs - CEO, Pouya Farmand. - The Market Herald Canada

" Levitee Labs (CSE:LVT) announces DTC eligibility

Common shares of Levitee Labs (LVT) are now eligible to be electronically cleared and settled through the DTC.
Avicanna Inc - CEO, Aras Azadian - The Market Herald Canada

" Avicanna (TSX:AVCN) files US patent application for cannabinoid formulation

Avicanna (AVCN) has filed a provisional patent application with the United States Patent and Trademark Office.
Alpha Cognition (TSXV:ACOG) announces $12.5 million public offering

" Alpha Cognition (TSXV:ACOG) announces $12.5 million public offering

Alpha Cognition (ACOG) has announced a C$12.5 million public offering led by Raymond James.